Respiratory syncytial virus nosocomial outbreak in neonatal intensive care: A review of the incidence, management, and outcomes.

Autor: Mosalli R; Department of Pediatrics, Umm Al-Qura University, Makkah, Saudi Arabia; Department of Pediatrics, International Medical Center, Jeddah, Saudi Arabia. Electronic address: rmmosalli@uqu.edu.sa., Alqarni SA; Medical College, Umm Al Qura University, Mecca, Saudi Arabia., Khayyat WW; Medical College, Umm Al Qura University, Mecca, Saudi Arabia., Alsaidi ST; Medical College, Umm Al Qura University, Mecca, Saudi Arabia., Almatrafi AS; Medical College, Umm Al Qura University, Mecca, Saudi Arabia., Bawakid AS; Medical College, Umm Al Qura University, Mecca, Saudi Arabia., Paes B; Department of Pediatrics (Neonatal Division), McMaster University, Hamilton, Ontario, Canada.
Jazyk: angličtina
Zdroj: American journal of infection control [Am J Infect Control] 2022 Jul; Vol. 50 (7), pp. 801-808. Date of Electronic Publication: 2021 Nov 01.
DOI: 10.1016/j.ajic.2021.10.027
Abstrakt: Background: The main objective was to determine the incidence, management, and outcomes of respiratory syncytial virus nosocomial infection (RSVNI) outbreaks in neonatal intensive care units.
Methods: A comprehensive search of RSVNI in 9 databases was conducted from January 1, 2000 to May 1, 2021, of which the Cochrane Library comprised the Cochrane central register of controlled trials and the Cochrane database of systematic reviews. Two hundred and twenty-eight articles were retrieved and 17 were retained. A descriptive analysis was performed, and frequencies are reported as mean, median, and range where pertinent.
Results: One hundred and seventeen infants were analyzed and comprised preterms (88.1%) and those with pre-existing co-morbidities. The estimated proportional incidence of RSVNI was 23.8% (177/744) infants. Outbreaks were principally managed by conventional protective measures, neonatal intensive care unit closure, and visitor restriction. Palivizumab was used to control RSVNI in 10 studies. RSVNI-related mortality was 8.5% (15/177) and 8.0% (7/87) among infants where infection control was solely employed.
Conclusion: RSVNI is associated with significant morbidity and mortality. The use of palivizumab should be a multidisciplinary decision, based on rapidly spreading infection. Prospective studies are essential to determine the cost-benefit of palivizumab versus standard prevention control for an RSVNI outbreak.
(Copyright © 2021 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: